
The treatment with the new diabetes drug is useful for certain diabetes patients. The Professional Association of diabetological specialist centers in North Rhine (BdSN) indicates that the active ingredient is wrote under certain conditions should be in order then to be able to contribute positively. “Patients on their current medication are well adjusted, but have no reason now to change the medicine,” said Dr. Ulrich Nühlen from BdSN. Liraglutide is in Germany and Britain since July on the market. The drug provides for that only increases with increased blood glucose, insulin is distributed. Thus, the drug not only lowers blood glucose levels but also reduces the risk of over-or hypo.
Since liraglutide acts over a relatively long period of time, diabetics have to inject only once a day under the skin. In the long term the drug may reduce the long-term value of sugar (HbA1c) by up to 1.2 percentage points. Studies were conducted to test the new medicament, have shown that often arise, however, side effects such as nausea or diarrhea, which usually subside with continued treatment. “Since the drug is new, we know nothing about long-term side effects,” adds Dr. Nühlen “were observed in the studies, although some 1000 patients, but only over a period of six months to a maximum of two years. Therefore, for a patient should Treatment with liraglutide are carefully selected and closely monitored in order to get it to further that perception. ”
Basically, the only drug for type 2 diabetes is likely to already taking tablets for diabetes and require no insulin. “Some people believe that they could simply switch to liraglutide and then never again need to inject insulin. However, this is a mistake,” says Dr. Matthias Riedel, liraglutide is no insulin rate. ” Even for a combination with insulin, the new drug is currently not allowed. In some years, could this combination, after appropriate investigations, however, turn out to be effective. Due to lack of experience liraglutide in patients with heart failure or inflammatory bowel disease should be prescribed with caution. Even in gastric paralysis of the drug should not be used. If symptoms of pancreatitis, liraglutide would be discontinued.
Because liraglutide compared with other diabetes medication is relatively expensive, it can be ordered from fi-nancial reasons, only in obese diabetic patients who transfer without the new drug would be dependent on insulin need and there because of their weight on very high doses. Here, liraglutide may also have a positive effect because the drug induces a feeling of satiety, which can lead to weight loss. Dr. Nühlen indicates that it is by no means the new drug is a miracle cure for obesity: “In the trials that patients have up to two percent of their body weight lost. The change in lifestyle is absolutely necessary with liraglutide . These include above all, more exercise and a balanced diet. ” In practice, it also showed significantly greater weight loss. The new product needs to be applied correctly and carefully.
“It is important containing that patients are well trained, so they know what not accompanying drug-free measures are necessary. This includes in addition to lifestyle changes such as the blood glucose self-monitoring”, explains Dr. Nühlen. “When patients leave due to insufficient training only on the drug, it will not work properly.” Organized the professional association of diabetologists doctors are able to share emerging findings in the regulation of new drugs with each other and immediately draw conclusions from them.
Background: The BdSN have the professional association of North Rhine diabetological Schwerpunktpraxen (BdSN) organized over 100 established diabetologists and helped shape the current favorable trends in the care of diabetes patients. The aim is to improve patient care suffering from diabetes further.
there is a rising incidence of Diabetes these days and you can blame high sugar diet and a lifestyle that is low on physical activities.